Strong sales of its COVID-19 vaccine and other medicines helped Pfizer nearly double its second-quarter revenue and boost its profit an impressive 59%, beating Wall Street expectations and leading the drug giant to sharply hike its 2021 sales and profit forecasts. Amid the surging coronavirus pandemic, the COVID-19 vaccine became Pfizer’s top seller, bringing in nearly half its revenue —$ 7.84 billion from direct sales and revenue split with its partner, Germany's BioNTech. Pfizer now anticipate
综合
ABC新闻-商业新闻
2021-07-28 00:00:00.0